S B Margolin
Overview
Explore the profile of S B Margolin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grattendick K, Nakashima J, Feng L, Giri S, Margolin S
Int Immunopharmacol
. 2008 Apr;
8(5):679-87.
PMID: 18387510
Tumor necrosis factor-alpha (TNF-alpha) is a vital component of the inflammatory process and its aberrant over-expression has been linked to numerous disease states. New treatment strategies have sought to reduce...
2.
Pesce E, Struma E, Giri S, Margolin S
Res Commun Mol Pathol Pharmacol
. 2007 Jun;
115-116:39-48.
PMID: 17564304
The antirheumatic effect of pirfenidone was compared with a positive control drug, oxyphenbutazone which is used in patients suffering from rheumatoid arthritis, in a double blind clinical trial in humans....
3.
Bruss M, Margolin S, Giri S
J Vet Pharmacol Ther
. 2004 Oct;
27(5):361-7.
PMID: 15500575
Pirfenidone, a promising antifibrotic agent, was administered orally to dogs at 0, 40, 140, and 400 mg/kg/day. Serum was collected for pirfenidone assay at 0, 26 and 39 weeks of...
4.
Giri S, Leonard S, Shi X, Margolin S, Vallyathan V
J Environ Pathol Toxicol Oncol
. 2004 Jul;
18(3):169-77.
PMID: 15281229
Pirfenidone is a newly developed antifibrotic drug that has been reported to retard the progression of pulmonary fibrosis induced by bleomycin and cyclophosphamide in animal models of lung fibrosis. The...
5.
Park H, Bao L, Kim Y, Cho I, Lee C, Hyun B, et al.
J Korean Med Sci
. 2003 Aug;
18(4):527-33.
PMID: 12923329
Pirfenidone (PFD) is a newly developed anti-fibrotic agent. We evaluated the effect of PFD for the prevention of renal fibrosis using a spontaneous progressive glomerulosclerosis animal model, FGS/Kist mice. Male...
6.
Waller J, Toomey D, Metcalfe M, Margolin S, Nicholson M
Transplant Proc
. 2002 Aug;
34(5):1486-8.
PMID: 12176451
No abstract available.
7.
Waller J, Murphy G, Bicknell G, Sandford R, Margolin S, Nicholson M
Eur J Vasc Endovasc Surg
. 2002 Mar;
23(3):234-40.
PMID: 11914010
Aims: intimal hyperplasia is mediated by smooth muscle cell proliferation, migration and deposition of extracellular matrix. The anti-fibrotic agent pirfenidone has been shown to inhibit pro-fibrotic growth factors in non-vascular...
8.
Hewitson T, Kelynack K, Tait M, Martic M, Jones C, Margolin S, et al.
J Nephrol
. 2002 Jan;
14(6):453-60.
PMID: 11783601
Background: Fibroblasts have been universally recognised in tubulointerstitial injury, where their presence has been shown to be a marker of disease progression. Recently, pirfenidone (PF) has been shown to both...
9.
Waller J, Murphy G, Metcalfe M, Bicknell G, Saunders R, Margolin S, et al.
Transplant Proc
. 2001 Dec;
33(7-8):3816-8.
PMID: 11750625
No abstract available.
10.
Walker J, Margolin S
Mult Scler
. 2001 Nov;
7(5):305-12.
PMID: 11724446
Current treatment of secondary progressive multiple sclerosis is unsatisfactory in stabilizing or reversing the disabilities associated with the disease. Pirfenidone is a new non-peptide drug which has been shown in...